Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1057) 1057
science & technology (985) 985
life sciences & biomedicine (957) 957
antiviral agents - therapeutic use (845) 845
hepatitis c, chronic - drug therapy (696) 696
sofosbuvir (652) 652
hepatitis c (605) 605
male (597) 597
sofosbuvir - therapeutic use (583) 583
female (545) 545
middle aged (531) 531
hepatitis c virus (516) 516
drug therapy, combination (491) 491
hepacivirus - genetics (429) 429
hepatitis (414) 414
genotype (407) 407
treatment outcome (405) 405
gastroenterology & hepatology (402) 402
ribavirin - therapeutic use (367) 367
adult (317) 317
aged (317) 317
hepatitis c - drug therapy (308) 308
interferon (295) 295
ribavirin (275) 275
uridine monophosphate - analogs & derivatives (271) 271
hepacivirus - drug effects (251) 251
antiviral agents - adverse effects (249) 249
antiviral agents (242) 242
uridine monophosphate - therapeutic use (236) 236
antiviral agents - administration & dosage (227) 227
pharmacology & pharmacy (223) 223
sustained virologic response (215) 215
hepatitis c, chronic - virology (210) 210
benzimidazoles - therapeutic use (208) 208
drug therapy (208) 208
infectious diseases (207) 207
health aspects (202) 202
liver (199) 199
fluorenes - therapeutic use (195) 195
patients (193) 193
care and treatment (187) 187
infections (184) 184
sofosbuvir - administration & dosage (181) 181
genotype & phenotype (175) 175
sofosbuvir - adverse effects (171) 171
liver cirrhosis (157) 157
hepatitis c, chronic - complications (154) 154
imidazoles - therapeutic use (154) 154
cirrhosis (150) 150
analysis (145) 145
genotypes (135) 135
simeprevir (135) 135
viruses (135) 135
abridged index medicus (133) 133
ledipasvir (129) 129
carbamates - therapeutic use (123) 123
daclatasvir (122) 122
sulfonamides - therapeutic use (119) 119
retrospective studies (117) 117
general & internal medicine (115) 115
viral load (115) 115
biological response modifiers (114) 114
medicine, general & internal (114) 114
liver transplantation (112) 112
virology (112) 112
transplantation (111) 111
ribavirin - administration & dosage (108) 108
genetic aspects (105) 105
young adult (102) 102
hcv (101) 101
virus diseases (100) 100
hepatology (98) 98
hepatitis c - virology (97) 97
recurrence (97) 97
simeprevir - therapeutic use (97) 97
gastroenterology and hepatology (96) 96
antiviral agents - economics (94) 94
heterocyclic compounds, 4 or more rings - therapeutic use (93) 93
liver cirrhosis - virology (93) 93
antiviral agents - pharmacology (89) 89
clinical trials (89) 89
liver cirrhosis - drug therapy (89) 89
direct-acting antivirals (88) 88
drug combinations (86) 86
interferon-alpha - therapeutic use (85) 85
hepacivirus - isolation & purification (83) 83
prospective studies (82) 82
viral nonstructural proteins - antagonists & inhibitors (82) 82
aged, 80 and over (80) 80
medical research (79) 79
microbiology (79) 79
ribavirin - adverse effects (78) 78
chronic infection (77) 77
rna, viral - blood (77) 77
immunology (75) 75
liver diseases (75) 75
research (75) 75
hepacivirus (74) 74
human immunodeficiency virus--hiv (70) 70
benzimidazoles - administration & dosage (68) 68
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1184) 1184
German (13) 13
Spanish (10) 10
Portuguese (7) 7
French (5) 5
Chinese (4) 4
Korean (2) 2
Czech (1) 1
Dutch (1) 1
Hungarian (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Direct‐acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN‐free treatment and future perspectives
by Asselah, Tarik and Boyer, Nathalie and Saadoun, David and Martinot‐Peignoux, Michele and Marcellin, Patrick
Liver international, ISSN 1478-3223, 01/2016, Volume 36, Issue S1, pp. 47 - 57
ledipasvir | sofosbuvir | dasabuvir grazoprevir | ombitasvir | velpatasvir | elbasvir | paritaprevir | Ombitasvir | Dasabuvir grazoprevir | Ledipasvir | Paritaprevir | Elbasvir | Velpatasvir | Sofosbuvir | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Sofosbuvir - therapeutic use | Anilides - therapeutic use | Benzofurans - therapeutic use | Antiviral Agents - therapeutic use | Humans | Fluorenes - therapeutic use | Cyclopropanes | Hepacivirus - genetics | Uracil - therapeutic use | Amides | Genotype | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Sulfonamides - therapeutic use | Female | Imidazoles - therapeutic use | Carbamates - therapeutic use | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Benzimidazoles - therapeutic use | Quinoxalines - therapeutic use | Uracil - analogs & derivatives | Virus diseases | Protease inhibitors | Proteases | Interferon | Drug therapy | Hepatitis C virus | Health aspects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study
by Evon, Donna M and Sarkar, Souvik and Amador, Jipcy and Lok, Anna S and Sterling, Richard K and Stewart, Paul W and Reeve, Bryce B and Serper, Marina and Reau, Nancy and Rajender Reddy, K and Di Bisceglie, Adrian M and Nelson, David R and Golin, Carol E and Lim, Joseph K and Fried, Michael W
Journal of hepatology, ISSN 0168-8278, 09/2019, Volume 71, Issue 3, pp. 486 - 497
Treatment | Sleep | Pain | Liver | Patient-reported outcome | HCV | PRO | Symptom | Quality of life | Functioning | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Anilides - therapeutic use | Benzimidazoles | Prospective Studies | Humans | Middle Aged | Fluorenes | Hepatitis C, Chronic - virology | Male | Cyclopropanes - therapeutic use | Young Adult | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Aged, 80 and over | Ritonavir - therapeutic use | Adult | Female | Imidazoles - therapeutic use | Drug Therapy, Combination | Patient Reported Outcome Measures | Quinoxalines - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Benzofurans - therapeutic use | Antiviral Agents - therapeutic use | Uracil - therapeutic use | Amides - therapeutic use | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Aged | Sustained Virologic Response | Carbamates - therapeutic use | Uracil - analogs & derivatives | Mental disorders | Ritonavir | Mental health | Chronic infection | Fatigue | Regression analysis | Patients | Cirrhosis | Hepatitis | Minimum inhibitory concentration | Hepatitis C | Index Medicus | sleep | treatment | functioning | pain | symptom | liver | patient-reported outcome | quality of life
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis
by Ji, Fanpu and Yeo, Yee Hui and Wei, Mike Tzuhen and Ogawa, Eiichi and Enomoto, Masaru and Lee, Dong Hyun and Iio, Etsuko and Lubel, John and Wang, Wenjun and Wei, Bin and Ide, Tatsuya and Preda, Carmen Monica and Conti, Fabio and Minami, Tatsuya and Bielen, Rob and Sezaki, Hitomi and Barone, Michele and Kolly, Philippe and Chu, Po-sung and Virlogeux, Victor and Eurich, Dennis and Henry, Linda and Bass, Michelle B and Kanai, Takanori and Dang, Shuangsuo and Li, Zongfang and Dufour, Jean-François and Zoulim, Fabien and Andreone, Pietro and Cheung, Ramsey C and Tanaka, Yasuhito and Furusyo, Norihiro and Toyoda, Hidenori and Tamori, Akihiro and Nguyen, Mindie H
Journal of hepatology, ISSN 0168-8278, 09/2019, Volume 71, Issue 3, pp. 473 - 485
Liver transplant | Non-Asian | HCC treatment | Asian | Real-world analysis | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Anilides - therapeutic use | Liver Transplantation | Humans | Fluorenes - therapeutic use | Liver Neoplasms - complications | Male | Hepatitis C, Chronic - complications | Young Adult | Carcinoma, Hepatocellular - complications | Ritonavir - therapeutic use | Adult | Female | Benzimidazoles - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Antiviral Agents - therapeutic use | Uracil - therapeutic use | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Adolescent | Isoquinolines - therapeutic use | Sustained Virologic Response | Carbamates - therapeutic use | Uracil - analogs & derivatives | Liver diseases | Syngeneic grafts | Ritonavir | Clinical trials | Chronic infection | Hepatocellular carcinoma | Systematic review | Risk factors | Liver cancer | Hepatitis | Allografts | Interferon | Hepatitis C | Liver transplantation | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world
by Pérez, Ana Belén and Chueca, Natalia and García-Deltoro, Miguel and Martínez-Sapiña, Ana María and Lara-Pérez, María Magdalena and García-Bujalance, Silvia and Aldámiz-Echevarría, Teresa and Vera-Méndez, Francisco Jesús and Pineda, Juan Antonio and Casado, Marta and Pascasio, Juan Manuel and Salmerón, Javier and Alados-Arboledas, Juan Carlos and Poyato, Antonio and Téllez, Francisco and Rivero-Juárez, Antonio and Merino, Dolores and Vivancos-Gallego, María Jesús and Rosales-Zábal, José Miguel and García, Federico and Ocete, María Dolores and Simón, Miguel Ángel and Rincón, Pilar and Reus, Sergi and De la Iglesia, Alberto and García-Arata, Isabel and Jiménez, Miguel and Jiménez, Fernando and Hernández-Quero, José and Galera, Carlos and Balghata, Mohamed Omar and Primo, Joaquín and Masiá, Mar and Espinosa, Nuria and Delgado, Marcial and von-Wichmann, Miguel Ángel and Collado, Antonio and Santos, Jesús and Mínguez, Carlos and Díaz-Flores, Felícitas and Fernández, Elisa and Bernal, Enrique and De Juan, José and Antón, José Joaquín and Vélez, Mónica and Aguilera, Antonio and Navarro, Daniel and Arenas, Juan Ignacio and Fernández, Clotilde and Espinosa, María Dolores and Ríos, María José and Alonso, Roberto and Hidalgo, Carmen and Hernández, Rosario and Téllez, María Jesús and Rodríguez, Francisco Javier and Antequera, Pedro and Delgado, Cristina and Martín, Patricia and Crespo, Javier and Becerril, Berta and Pérez, Óscar and García-Herola, Antonio and Montero, José and Freyre, Carolina and Grau, Concepción and GEHEP-004 Study Group and GEHEP-004 Study Grp
Journal of hepatology, ISSN 0168-8278, 11/2019, Volume 71, Issue 5, pp. 876 - 888
Resistance testing | RASs | Treatment failure | HCV | Resistance-associated substitution | Ribavirin | Direct-acting antivirals | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Anilides - therapeutic use | Prospective Studies | Hepatitis C - drug therapy | Humans | Middle Aged | Fluorenes - therapeutic use | Hepacivirus - genetics | Male | Cyclopropanes - therapeutic use | Hepatitis C - epidemiology | Ritonavir - therapeutic use | Female | Imidazoles - therapeutic use | Lactams, Macrocyclic - therapeutic use | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Sofosbuvir - therapeutic use | Antiviral Agents - pharmacology | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Viral Nonstructural Proteins - genetics | Genotype | Proline - therapeutic use | Retreatment | Drug Resistance, Viral - genetics | Sulfonamides - therapeutic use | Spain - epidemiology | Hepatitis C - virology | Sustained Virologic Response | Carbamates - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Disease resistance | Antiviral agents | Hepatitis | Ritonavir | New combinations | Interferon | Hepatitis C | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice
by Backus, L. I and Belperio, P. S and Shahoumian, T. A and Loomis, T. P and Mole, L. A
Alimentary pharmacology & therapeutics, ISSN 0269-2813, 08/2016, Volume 44, Issue 4, pp. 400 - 410
Anilides - therapeutic use | Humans | Middle Aged | Fluorenes - therapeutic use | African Americans | Hepacivirus - genetics | Male | RNA, Viral - blood | Young Adult | Aged, 80 and over | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Sofosbuvir - therapeutic use | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Aged | Sustained Virologic Response | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Medicine | Care and treatment | RNA | Practice | Genetic aspects | Comparative analysis | Hepatitis C virus | Hepatitis C | Ribavirin | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US
by Zhang, Sai and Bastian, Nathaniel D and Griffin, Paul M
BMC gastroenterology, ISSN 1471-230X, 08/2015, Volume 15, Issue 1, pp. 98 - 98
Chronic hepatitis C | Olysio | Viekira Pak | Harvoni | Markov model | Cost-effectiveness | Sofosbuvir | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Interferons - economics | Markov Chains | Fluorenes - economics | Ribavirin - economics | Humans | Middle Aged | Simeprevir - economics | Fluorenes - therapeutic use | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Ritonavir - economics | Male | Interferons - therapeutic use | Uridine Monophosphate - economics | Benzimidazoles - economics | Polyethylene Glycols - therapeutic use | Simeprevir - therapeutic use | Sofosbuvir - economics | Ritonavir - therapeutic use | Female | Macrocyclic Compounds - economics | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Quality-Adjusted Life Years | Sofosbuvir - therapeutic use | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Drug Therapy, Combination - economics | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Cost-Benefit Analysis | Sulfonamides - economics | Uridine Monophosphate - analogs & derivatives | Uracil - economics | Antiviral Agents - economics | Drug Combinations | Uracil - analogs & derivatives | Economic aspects | Markov processes | Hepatitis C virus | Analysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register)
by Wiegand, Johannes and Buggisch, Peter and Mauss, Stefan and Boeker, Klaus H.W and Klinker, Hartwig and Müller, Tobias and Günther, Rainer and Serfert, Yvonne and Manns, Michael P and Zeuzem, Stefan and Berg, Thomas and Hinrichsen, Holger and C-Registry, German Hepatitis and German Hepatitis C-Registry
European journal of gastroenterology & hepatology, ISSN 0954-691X, 11/2019, Volume 31, Issue 11, pp. 1424 - 1431
Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Anilides - therapeutic use | Pleural Effusion - chemically induced | Humans | Middle Aged | Fluorenes - therapeutic use | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Renal Insufficiency, Chronic - complications | Simeprevir - therapeutic use | Renal Insufficiency, Chronic - metabolism | Hypertension - chemically induced | Ritonavir - therapeutic use | Adult | Female | Registries | Imidazoles - therapeutic use | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Severity of Illness Index | Sofosbuvir - therapeutic use | Liver Cirrhosis - etiology | Acute Disease | Glomerular Filtration Rate | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Anemia - chemically induced | Uracil - therapeutic use | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | Disease Progression | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Uridine Monophosphate - analogs & derivatives | Aged | Sustained Virologic Response | Carbamates - therapeutic use | Germany | Uracil - analogs & derivatives | Antiviral agents | Care and treatment | Usage | Chronic kidney failure | Hepatitis C | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
by Bourlière, Marc and Gordon, Stuart C and Flamm, Steven L and Cooper, Curtis L and Ramji, Alnoor and Tong, Myron and Ravendhran, Natarajan and Vierling, John M and Tran, Tram T and Pianko, Stephen and Bansal, Meena B and de Lédinghen, Victor and Hyland, Robert H and Stamm, Luisa M and Dvory-Sobol, Hadas and Svarovskaia, Evguenia and Zhang, Jie and Huang, K.C and Subramanian, G. Mani and Brainard, Diana M and McHutchison, John G and Verna, Elizabeth C and Buggisch, Peter and Landis, Charles S and Younes, Ziad H and Curry, Michael P and Strasser, Simone I and Schiff, Eugene R and Reddy, K. Rajender and Manns, Michael P and Kowdley, Kris V and Zeuzem, Stefan and POLARIS-1 and POLARIS-4 Investigators and POLARIS-1 and POLARIS-4 Investigators
The New England journal of medicine, ISSN 0028-4793, 06/2017, Volume 376, Issue 22, pp. 2134 - 2146
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hepatitis C - drug therapy | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Male | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Aged, 80 and over | Adult | Female | Hepatitis C - complications | Sofosbuvir - adverse effects | Protease Inhibitors - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Genotype | Heterocyclic Compounds, 4 or More Rings - adverse effects | Macrocyclic Compounds - adverse effects | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Hepatitis C - virology | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Drug Combinations | Care and treatment | Hepatitis C virus | Drug therapy | Patients | Health aspects | Headache | Antiretroviral drugs | Antiviral agents | Proteinase | Clinical trials | Diarrhea | Fatigue | Nausea | Cirrhosis | Hepatitis | Genotypes | Pharmaceuticals | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text English hepatitis C registry data show high response rates to directly acting anti‐virals, even if treatment is not completed
by Drysdale, Kathryn and Ntuli, Yevedzo and Bestwick, Jonathan and Gelson, William and Agarwal, Kosh and Forton, Daniel and Mutimer, David and Elsharkawy, Ahmed M and Townley, Ceri and Mahomed, Faizel and Foster, Graham R
Alimentary pharmacology & therapeutics, ISSN 0269-2813, 07/2020, Volume 52, Issue 1, pp. 168 - 181
Gastroenterology & Hepatology | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Anilides - therapeutic use | Hepatitis C - drug therapy | Humans | Middle Aged | Fluorenes - therapeutic use | England | Male | Young Adult | Aged, 80 and over | Adult | Female | Registries | Imidazoles - therapeutic use | Benzimidazoles - therapeutic use | Quinoxalines - therapeutic use | Uridine Monophosphate - therapeutic use | Benzofurans - therapeutic use | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Macrocyclic Compounds - therapeutic use | Uridine Monophosphate - analogs & derivatives | Adolescent | Aged | Sustained Virologic Response | Carbamates - therapeutic use | Drug Combinations | Sofosbuvir | Hepatitis C | Genotypes | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights